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Summary
 
OBJECTIVE
 
 
 
Data on bone mineral density (BMD) in
acromegaly are conflicting as most previous studies
collectively evaluated eugonadal and hypogonadal
patients of both sexes, with or without active disease.
We have evaluated BMD in 152 acromegalic patients
of both sexes with varying disease activity and
gonadal status.
 
DESIGN
 
 
 
Cross-sectional, retrospective.
 
PATIENTS
 
 
 
We studied 152 acromegalic patients (99
women aged 26–72 years, and 53 men aged 21–
75 years), 107 with active and 45 with controlled dis-
ease. Eighty-five patients had normal gonadal status
and 67 were hypogonadal.
 
MEASUREMENTS
 
 
 
In all patients we measured serum
GH levels by immunoenzimometric assay, and serum
IGF-I levels by radioimmunoassay. BMD was assessed
at spine L2–L4 (LS) and at femoral neck (FN) by dual
energy X-ray absorptiometry; results are expressed as
 
Z
 
-values.
 
RESULTS
 
 
 
We evaluated the effect of GH excess on
bone at different sites in relation to gonadal status,
disease activity and gender. At LS, in respect to the
reference population, BMD (mean ±
 
 SE) values were
higher in eugonadal patients (active: 0·71 ±
 
 0·29,
 
P
 
 < 0·02; controlled: 0·65 ±
 
 0·28, 
 
P
 
 < 0·05) and lower in
hypogonadal ones (active: −
 
0·64 ±
 
 0·35, 0·1 < 
 
P
 
< 0·05;
controlled: −
 
1·05 ±
 
 0·36, 
 
P
 
 < 0·01), regardless of dis-
ease activity. On the contrary, at FN, BMD was higher
than in the reference population, both in eugonadal
(1·01 ±
 
 0·22, 
 
P
 
 < 0·001) and hypogonadal (0·63 ±
 
 0·17,
 
P
 
 < 0·001) patients only in subjects with active dis-
ease, but not in those in which the disease was con-
trolled (eugonadal: 0·31 ±
 
 0·23, 
 
P
 
 = ns; hypogonadal
0·04 ±
 
 0·28, 
 
P
 
 = ns). We did not observe any difference
in BMD values according to gender both at LS (males
 
vs.
 
 females −
 
0·02 ±
 
 0·30 
 
vs.
 
 0·01 ±
 
 0·24, 
 
P
 
 = ns) or at FN
(0·77 ±
 
 0·19 
 
vs.
 
 0·63 ±
 
 0·15, 
 
P
 
 = ns).
 
CONCLUSIONS
 
 
 
The anabolic effect of GH excess on bone
in acromegalic patients is: (i) gender-independent;
(ii) evident at the spine only in eugonadal regardless
of disease activity; (iii) evident at femoral neck only
in the presence of active disease regardless of gonadal
status.
 
It has been known for over 50 years that acromegaly affects bone
(Albright & Reifeinstein, 1948). However, data on bone mineral
density (BMD) in these patients are still conflicting. Seeman
 
et al
 
. (1982) detected increased spinal BMD in seven patients
with active acromegaly. Diamond 
 
et al
 
. (1989) observed reduced
spinal BMD in 12 hypogonadal patients but 12 eugonadal
patients did not show any difference with respect to controls at
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the spine, while forearm BMD was increased in patients with
active disease. Ezzat 
 
et al
 
. (1993) showed that spinal BMD was
not different from controls in seven eugonadal patients with
active disease, while it was reduced in seven hypogonadal
patients with active disease. Ho 
 
et al
 
. (1992) observed 25 patients
with active disease, eight eugondal and 17 hypogonadal subjects,
and did not observe any difference at spine and femur BMD with
respect to controls. Kotzman 
 
et al
 
. (1993) examined 16 patients
with active disease, four eugonadal and 12 hypogonadal, and
detected increased BMD at spine and femur. Kayath & Vieira
(1997) studied 45 patients (11 eugonadal and 34 hypogonadal
subjects) with active disease and did not report changes in BMD
measured at spine and femur. Lesse 
 
et al
 
. (1998) studied 18
patients (10 with active disease and 12 hypogonadal subjects) and
analysed data in terms of activity of disease and gonadal status,
in eugonadal patients detected higher BMD at spine and femur,
and in hypogonadal patients reduced spinal BMD. Longobardi
 
et al
 
. (1998) studied 11 patients with active disease (six eugo-
nadal and five hypogonadal) and demonstrated a reduced spinal
BMD. Kaji 
 
et al
 
. (2001) examined 26 patients with active dis-
ease, and found higher BMD at the spine, femur and forearm
areas compared to controls. There are several reasons for these
conflicting results: the small sample size of previous studies, and
in some of these studies the lack of patient stratification and sep-
arate analysis according to gender, disease activity and gonadal
status. Moreover, BMD was measured at different skeletal sites,
whose behaviour with respect to GH excess and hypo- or eugo-
nadal status could be divergent and therefore not comparable
(Diamond 
 
et al
 
., 1989; Ho 
 
et al
 
., 1992; Kotzman 
 
et al
 
., 1993;
Kayath & Vieira, 1997; Lesse 
 
et al
 
., 1998; Longobardi 
 
et al
 
.,
1998). To investigate the skeletal involvement in acromegalic
patients, and to evaluate the effect of the aforementioned factors,
a large sample of patients is needed. Therefore, we retrospec-
tively evaluated BMD both at spine and at femoral neck in over
150 acromegalic patients, enrolled in nine referral Italian centres,
which participated in the Italian Study Group of Acromegaly
under the auspices of the Italian Society of Endocrinology (SIE).
 
Patients and methods
 
Patients
 
One hundred and seventy-three acromegalic patients, referred to
nine centres in Italy, were initially studied. In all patients, the
diagnosis of acromegaly had been suspected by clinical features
and confirmed by high serum GH levels not suppressible below
1 
 
µ
 
g / l after oral glucose tolerance test (OGTT) and high serum
IGF-I level compared to gender and age-related normal values.
At the time of observation, 41 patients had been diagnosed
recently. The remaining 132 patients had been previously sub-
mitted to one or more of the following treatments: surgery (90),
radiotherapy (40), or pharmacological therapy with long-acting
agonists of somatostatin or dopamine agonists (104). Twenty-one
patients were excluded from the study because they were either
affected by concomitant diseases (six by thyrotoxicosis, three by
breast cancer, one by lymphoma and one by progressive systemic
sclerosis) or they had been treated with therapeutic agents (six
alendronate and four high-dose corticosteroids) known to affect
bone metabolism and influence BMD.
Therefore we finally studied 152 patients: 99 women (aged 26–
72 years, mean 
 
±
 
 SE 50·8 
 
±
 
 1·13 years) and 53 men (aged 21–
75 years, mean 
 
±
 
 SE 48·1 
 
±
 
 1·75 years). According to IGF-I
serum levels, patients were subdivided in ‘active’ and ‘control-
led’ groups on the basis of specific gender- and age-adjusted ref-
erence range (Giustina 
 
et al
 
., 2000). At the time of observation,
serum IGF-I levels were within the normal range according to
gender and age in 45 patients (33 women, 12 men); in 23 of these
patients, disease activity had been controlled by surgery and/or
radiotherapy and in 22 by pharmacological therapy. However,
among these 45 patients, 15 had mean serum GH levels higher
than 2·5 
 
µ
 
g / l, which is considered the upper limit for an adequate
control of acromegaly (Giustina 
 
et al
 
., 2000). Serum IGF-I levels
were higher than normal in 107 patients. The duration of disease
was estimated by interviewing the patients about the time of onset
of acral enlargement and by watching patient’s photographs over
the previous decades. The estimated time of onset of acromegaly
was after 19 years of age for all patients.
Eighty-five patients (66 females and 19 males) were eugo-
nadal, whereas 67 patients were hypogonadal (33 females and
34 males). The duration of hypogonadism was estimated by
interviewing all patients about symptoms, taking into account
their menstrual history and serum oestradiol levels (oestradiol
<110·1 pmol/ l) in females, and serum testosterone levels
(testosterone < 8·67 nmol/l; Anonymous, 2001) in males. Length
of hypogonadism in female patients, who were not on sex steroid
replacement therapy, was arbitrarily defined as lasting from the
time of onset of symptoms to the age of 50 years, which is the
mean menopausal age of Italian women (Parazzini 
 
et al
 
., 1992).
At the time of observation, patients on sex steroid replacement
therapy (eight females and eight males with active disease, seven
females and five males with controlled disease) had been treated
for at least 5 years. Thirty patients were on substitutive gluco-
corticoid and/or thyroid hormone therapy. None of the patients
had renal or hepatic impairment and none consumed substances
known to affect bone metabolism. All patients gave their wit-
nessed informed consent before entering the study, whose design
was made according to the Helsinki Declaration II.
 
Patients’ classifications
 
According to the above characteristics, patients were analysed
either as a whole group or in different subgroups according to
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disease activity (active/controlled) or gender (male/female).
Within these groups, patients were also further subdivided
according to gonadal status (eugonadism, hypogonadism).
 
Measurements
 
In all patients, a general biochemical profile of the serum plus
evaluation of thyroid function was performed to exclude diseases
influencing bone metabolism. Serum GH levels were measured
by immunoenzymometric assay (Eurogenetic Italy, Turin, Italy);
intra- and interassay CVs were 3·3–2·6–2·7% and 4·2–5·4–4·3%,
respectively, at the mean concentration of 2·8–23·6–42·2 
 
µ
 
g / l.
Serum IGF1 levels were evaluated by radioimmunoassay (RIA)
after acid-ethanol extraction (Nichols Institute Diagnostics, BT
Wychen, the Netherlands); intra- and interassay CVs (IGF1) were
2·4–3·0–3·6% and 5·2–8·4–6·8%, respectively, at the mean con-
centration of 119·2–207–540 
 
µ
 
g / l.
In all patients, BMD was measured at spine (L2–L4) and/or
at femoral neck by dual X-ray absorptiometry (DXA) using
Hologic (110 patients, 66 with active disease and 44 with con-
trolled disease; Hologic Inc, Waltham, MA, USA) or Norland (42
patients, 39 with active disease and three with controlled disease;
Norland Instruments, Fort Atkinson, WI, USA) densitometers,
whose 
 
in vitro
 
 mean precision at spine and femoral neck was 1·0
and 2·3%, respectively. BMD was not measured at lumbar spine
(LS, L2–L4) in 24 patients, and at femoral neck (FN) in 17
patients because of arthropathic involvement at spine or hip,
vascular calcifications or spinal fractures evidenced by X-ray of
lumbar spine and hip.
In order to evaluate volumetric trabecular bone density in 40
patients (23 females and 17 males) with active disease, spinal
trabecular BMD was measured also by single-energy quantitative
computed tomography L1–L4 (QCT; Toshiba CT Xpeed;
Toshiba Medical Systems Division, Tokyo, Japan; 
 
in vivo
 
 preci-
sion 1·8%).
In order to express BMD data with respect to the different ages
and gender of patients and to the different devices, BMD data
were expressed as SD units (or Z-transformed) by relating them
to the reference population of each centre (Scillitani 
 
et al
 
., 1997).
Bone mass in the reference population of each centre was com-
parable to each of the others (Guglielmi 
 
et al
 
., 1995).
 
Statistical analyses
 
Results are expressed as mean 
 
±
 
 SE. Significant difference was
assumed at 
 
P
 
 < 0·05. Significant differences in BMD between
patients and reference population were assumed when BMD Z-
values divided by SE were greater than 
 
t
 
-value according to the
sample size (Lesse 
 
et al
 
., 1998).
The comparison between patients with active and controlled
disease, and that between women and men, was performed using
unpaired 
 
t
 
-test or Mann–Whitney 
 
U
 
-test, as appropriate. Cate-
gorical variables were analysed by 
 
χ
 
2
 
 test.
In order to compare data of different subgroups stratified by
disease activity or sex and gonadal status (i.e. eugonadal and
hypogonadal patients of different sex; eugonadal and hypogo-
nadal patients with active or controlled disease) one-way analysis
of variance (
 
ANOVA
 
) and Bonferroni 
 
post hoc
 
 analysis were
performed.
In order to evaluate at LS the correlation between volumetric
BMD measured by QCT and areal BMD measured by DXA,
Spearman rank order correlation was performed.
Multiple regression analysis was performed considering BMD
as dependent variable, and IGF-I levels, ‘duration of acromegaly’
and ‘duration of hypogonadism’ as independent variables.
 
Results
 
Relationship between BMD and disease activity
 
The characteristics of active or controlled patients are shown in
Table 1. Except for GH levels, age, BMI, disease duration, pro-
portion of eugonadal and hypogonadal subjects and duration of
hypogonadism were similar in active and controlled patients.
Table 1 Clinical characteristics of the patients studied according to disease activity
 
 
Active Controlled P-value
IGF-I (µg/l) 800 ± 33 (348– 1976) 218 ± 17 (24–466) < 0·0001
Sample size (n) 107 45
Age (years) 49·5 ± 1·1 (21–75) 50·6 ± 1·8 (29–72) 0·66
BMI (kg/m2) 28·3 ± 0·5 (20·8–41·1) 27·4 ± 0·8 (20–40·7) 0·13
Duration of disease (years) 11·7 ± 0·8 (1–40) 11·2 ± 1·2 (2–35) 0·77
GH (µg/l) 23·7 ± 3·0 (1·8–374) 2·3 ± 0·3 (0·2–10·3) < 0·0001
Eugonadal /Hypogonadal 60/47 25/20 0·90
Duration of hypogonadism (years) 5·8 ± 0·6 (1–20) 7·6 ± 1·5 (1–23) 0·68
Data are expressed as mean ± SEM (range in parentheses).
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Corticosteroid or thyroxine dosages and percentage of patients
consuming these drugs did not significantly differ between sub-
jects with active and controlled disease (data not shown).
As shown in Fig. 1 and Table 2, BMD at LS was higher in eug-
onadal and lower in hypogonadal patients than in the reference
population, regardless of disease activity. Moreover, a significant
difference between eugonadal and hypogonadal patients was
found both in the active and controlled groups.
As shown in Fig. 2 and Table 2, BMD at FN was significantly
higher in the whole sample and in subjects with active disease
than in the reference population, independent of gonadal status.
In contrast, BMD at FN did not differ from the reference popu-
lation in patients with controlled disease. Furthermore, BMD at
FN was higher in patients with active disease than in patients with
controlled disease (P = 0·018).
By restricting the analysis to the 111 patients who measured
BMD at both LS and FN, we observed similar results (data not
shown). When subdividing the sample of ‘controlled’ patients on
the basis of GH levels (above or below 2·50 µg/l) we did not
observe any difference between these subgroups regarding BMD
values (Table 3). Moreover, we performed a subanalysis in con-
trolled patients not taking somatostatin analogues, as these drugs
could affect bone  (Table 4). The results were comparable to those
obtained in the all group of controlled patients.
Relationship between BMD and gender
Male and female patients did not differ for age, BMI, duration
of disease, serum GH and IGF-I levels, proportion of active and
controlled subjects and duration of hypogonadism, while hypog-
onadism was more common in males (Table 5).
Fig. 1 BMD measured at lumbar spine in active and controlled 
acromegalic patients with different gonadal status. Data are expressed 
as Mean ± SEM. °P < 0·05 vs. reference population; *P < 0·01 vs. 
reference population. §P < 0·001 vs. hypogonadal patients. One-way 
ANOVA: ^P < 0·05 vs. hypogonadal patients of the same group.
Table 2 Bone mineral density (BMD) measured at lumbar spine (LS) and femoral neck (FN) of active or controlled acromegalic patients with different 
gonadal status
 
 
LS FN 
n BMD P-value n BMD P-value
Whole sample 128 −0·03 ± 0·19 ns 135 0·68 ± 0·12 < 0·001
Eugonadal 66 0·70 ± 0·23§ < 0·01 76 0·82 ± 0·17 < 0·001
Hypogonadal 62 −0·75 ± 0·27 < 0·01 59 0·50 ± 0·15 < 0·002
Active disease 95 0·07 ± 0·24 ns 101 0·84 ± 0·14^ < 0·001
Eugonadal 50 0·71 ± 0·29* < 0·05 55 1·01 ± 0·22 < 0·001
Hypogonadal 45 −0·64 ± 0·35 0·1 < P < 0·05 46 0·63 ± 0·17 < 0·001
Controlled disease 33 −0·23 ± 0·27 ns 34 0·21 ± 0·18 ns
Eugonadal 16 0·65 ± 0·28* < 0·05 21 0·31 ± 0·23 ns
Hypogonadal 17 −1·05 ± 0·36 < 0·01 13 0·04 ± 0·28 ns
Data are expressed as mean ± SE. n = sample size. BMD values are expressed in terms of Z-values. P are referred to comparisons with reference 
population. ^P = 0·018 vs. patients with controlled disease. §P < 0·001 vs. hypogonadal patients. One-way ANOVA was performed to compare the 
BMDs of eugonadal and hypogonadal patients with active and controlled disease measured at the two skeletal sites: *P < 0·05 vs. hypogonadal patients 
of the same group.
Fig. 2 BMD measured at femoral neck in active and controlled 
acromegalic patients with different gonadal status. Data are expressed 
as Mean ± SEM. °P < 0·002 vs. reference population; *P < 0·001 vs. 
reference population. ^P = 0·018 vs. patients with controlled disease.
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As shown in Fig. 3, the effect of GH excess on BMD measured
at LS and FN was not influenced by gender.
Correlations
Bone mass at LS performed by QCT highly directly correlated
with areal BMD measured by DXA (r = 0·75, P < 0·001).
Multiple regression analysis showed that BMD at LS was inversely
correlated with ‘duration of hypogonadism’ (r = −0·30, P < 0·001;
R2 = 0·07) and positively correlated with ‘duration of acromeg-
aly’ (r = 0·23, P < 0·01; R2 = 0·05), but not with IGF-I levels.
Multiple regression analysis showed that BMD at FN was pos-
itively correlated with IGF-I levels (r = 0·26, P < 0·01; R2 = 0·06) but
not with ‘duration of hypogonadism’ or ‘duration of acromegaly’.
Table 3 Bone mineral density (BMD) measured at lumbar spine (LS) 
and femoral neck (FN) of controlled acromegalic patients with different 
GH levels (above or below 2·5 µg/l) and different gonadal status
 
 
LS FN 
n BMD n BMD
GH > 2·5 µg/l
Eugonadal 7 0·36 ± 0·29 9 0·11 ± 0·42
Hypogonadal 5 −0·83 ± 0·66 3 −0·12 ± 0·85
GH < 2·5 µg/l
Eugonadal 9 0·87 ± 0·45* 12 0·47 ± 0·26
Hypogonadal 12 −1·13 ± 0·44 10 0·08 ± 0·27
Data are expressed as mean ± SE. n = sample size. BMD values are 
expressed in terms of Z-values. One-way ANOVA was performed to 
compare the BMDs of eugonadal and hypogonadal patients with 
controlled disease and GH levels above or below 2·5 µg/l, measured 
at the two skeletal sites. = P < 0·05 vs. hypogonadal patients of the 
same group.
 
LS FN 
n BMD P-value n BMD P-value
Controlled disease
Eugonadal 5 1·18 ± 0·47 0·1 < P < 0·05 6 0·46 ± 0·27 ns
Hypogonadal 10 −0·99 ± 0·52 0·1 < P < 0·05 8 −0·15 ± 0·43 ns
Data are expressed as mean ± SE. n = sample size. BMD values are expressed in terms of 
Z-values. P are referred to comparisons with reference population.
Table 4 Bone mineral density (BMD) measured at 
lumbar spine (LS) and femoral neck (FN) of 
controlled acromegalic patients with different 
gonadal status, not taking somatostatin analogues
Table 5 Clinical characteristics of the patients studied according to gender
 
 
Males (n = 53) Females (n = 99) P-value
Age (years) 48·1 ± 1·7 (21–75) 50·8 ± 1·1 (26–72) 0·18
BMI (kg/m2) 28·3 ± 0·5 (22–40·7) 27·8 ± 0·5 (20–41·1) 0·18
Duration of disease (years) 11·1 ± 1·0 (1–30) 11·8 ± 0·8 (2–40) 0·56
GH (µg/l) 15·0 ± 3·6 (0·4–125) 18·7 ± 4·4 (0·2–374) 0·98
IGF-I (µg/l)  616 ± 46 (65–1432)  636 ± 43 (24–1976) 0·90
Active/Controlled 41/12 66/33 0·23
Eugonadal /Hypogonadal 19/34 66/33 0·0005
Duration of hypogonadism (years) 5·5 ± 0·70 (1–16) 7·36 ± 0·98 (1–23) 0·19
Data are expressed as mean ± SEM (range in parentheses). BMI, body mass index.
Fig. 3 BMD measured according to gender at lumbar spine (LS) and 
femoral neck (FN) in acromegalic patients with different gonadal status. 
Data are expressed as Mean ± SEM. ^P < 0·05 vs. reference population; 
*P < 0·01 vs. reference population; °P < 0·001 vs. reference population. 
One-way ANOVA: ∼P < 0·05 vs. BMD measured at spine in hypogonadal 
patients of the same gender.
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Discussion
To the best of our knowledge, this is the largest study performed
to evaluate the effects of acromegalic disease on BMD. Several
previous studies have provided conflicting results when investi-
gating small series of patients (Diamond et al., 1989; Ho et al.,
1992; Ezzat et al., 1993; Kotzman et al., 1993; Kayath & Vieira,
1997; Lesse et al., 1998; Longobardi et al., 1998; Chiodini I
et al., 2001). This might be due to several factors. First, enrol-
ment of patients with active or inactive disease, therefore with a
wide range of GH and IGF-I levels. Second, in acromegaly, the
deficiency of gonadal hormones due to the high prevalence of
hypogonadism (Katznelson et al., 2001) is an important factor
modulating bone metabolism. Finally, these modulating variables
might differently influence bone tissue at LS and FN. In our opin-
ion the conflicting results reported in previous papers could be
due to the small samples studied and to the heterogeneity of dif-
ferent series (Diamond et al., 1989; Ho et al., 1992; Ezzat et al.,
1993; Kotzman et al., 1993; Kayath & Vieira, 1997; Lesse et al.,
1998; Longobardi et al., 1998). For these reasons, we studied a
large sample of acromegalics to evaluate the effect of GH excess
on bone at different sites in relation to gender, gonadal status and
disease activity. Our study suffers some limitations mainly due
to its retrospective design: in particular, the different devices uti-
lized and the availability of only areal BMD in a disease in which
bone geometry could be altered. To overcome these limits, we
expressed BMD data as Z-values in respect to control population
of each centre; furthermore we also evaluated spinal trabecular
volumetric bone mass in a subgroup of patients with active dis-
ease by QCT. The strong correlation of BMD measured by QCT
and DXA, which is well known in normal subjects, suggests that
in our active acromegalic patients data on areal BMD are inform-
ative of those on volumetric bone mass, at least in trabecular
bone.
Our data show that at spine BMD was higher in eugonadal and
lower in hypogonadal patients compared with controls. This find-
ing demonstrates that at the spine the anabolic effect of GH
becomes evident only in the presence of a normal gonadal status,
whereas it is overridden by the catabolic effect of hypogonadism.
This effect is independent of disease activity and gender. Our
findings suggest therefore that conflicting results reported in the
literature are likely to be partially due to a different prevalence
of eu- and hypogonadal patients in their samples (Diamond et al.,
1989; Ho et al., 1992; Ezzat et al., 1993; Kotzman et al., 1993;
Kayath & Vieira, 1997; Lesse et al., 1998; Longobardi et al., 1998).
BMD at FN was higher in acromegalic patients with active dis-
ease than in controls, independent of gonadal status. This finding
suggests that at this site the anabolic effect of GH excess over-
comes the catabolic effect of hypogonadism. Once again, no gen-
der effect was observed. Our finding of different effects of
hypogonadism, on either LS or FN in active acromegaly, is in
agreement with recently reported data in an animal model (Mori-
moto et al., 2000). No difference was observed at FN between
patients with controlled disease and reference population, sug-
gesting that at this skeletal site the anabolic effect of previous
chronic GH excess is reversible.
BMD at the FN did not correlate with ‘duration of disease’
and ‘duration of hypogonadism’, probably due to the cross-
sectional design of our study. The multiple regression analysis,
however, showed that disease activity, as evaluated by IGF-I,
significantly correlated with BMD measured at FN, a site com-
posed prevalently of cortical bone. Our observation is in agree-
ment with the previously observed association between BMD
measured at forearm and serum IGF-I levels (Diamond et al.,
1989), suggesting that the anabolic effect of chronic GH excess
is more evident at cortical bone. Our data suggest that this effect
is lost after normalization of IGF-I levels. BMD at spine corre-
lated with ‘duration of acromegaly’ and ‘duration of hypogonad-
ism’ and confirms that GH excess exerts its anabolic effect in
relationship to gonadal status at a prevalently trabecular site
such as LS. This effect is not lost after normalization of IGF-I
levels. However, great caution is needed in this issue because in
order to evaluate the impact of duration of the disease, duration
of hypogonadism and disease activity on the bone, the cross-
sectional design of our study could be inappropriate, and a
longitudinal study should be performed to address these issues.
In conclusion, our data indicate that the anabolic effect of GH
excess on bone in acromegalic patients is: (i) gender-independent;
(ii) evident at spine only in eugonadal status regardless for dis-
ease activity; and (iii) evident at femoral neck only in presence
of active disease regardless for gonadal status.
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